Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CDC25A | P30304 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402591 | 0.98 | PTPN1 (0.35) | PTPN1CHRNA7CDC25ACDC25B | |
| SCHEMBL6408424 | 0.86 | CHRNA7 (0.32) | CHRNA7 | |
| SCHEMBL6401039 | 0.86 | MEN1 (0.36) | MEN1POLBKMT2AATM | |
| SCHEMBL6406442 | 0.85 | MME (0.30) | — | |
| SCHEMBL6401073 | 0.85 | MEN1 (0.35) | CHRNA7MEN1POLBKMT2AATM | |
| SCHEMBL6401912 | 0.83 | — | — | |
| SCHEMBL6403915 | 0.83 | MEN1 (0.31) | MEN1POLBKMT2AATM | |
| SCHEMBL6407257 | 0.81 | BCHE (0.31) | CHRNA7 | |
| SCHEMBL6402561 | 0.81 | BCHE (0.34) | — | |
| SCHEMBL6400675 | 0.81 | MEN1 (0.30) | CHRNA7MEN1POLBKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844288-B2 | Process for the preparation of ligands for metallogene catalysts | BASELL POLYOLEFINE GMBH (DE) | 2005-01-18 | — | — | US | disclosed |
| US-20030158356-A1 | Process for the preparation of substantially amorphous alpha-olefin polymers and compositions containing them and process for the preparation of bridged ligand | EQUISTAR CHEMICALS, LP | 2003-08-21 | — | — | US | disclosed |
| US-20020169260-A1 | Process for the preparation of ligands for metallocene catalysts | RESCONI LUIGI (IT) | 2002-11-14 | — | — | US | disclosed |
| US-6423796-B1 | COORDINATION CATALYST | BASEL TECHNOLOGY COMPANY BV (NL) | 2002-07-23 | — | — | US | disclosed |
| WO-2000001738-A9 | PROCESS FOR THE PREPARATION OF SUBSTANTIALLY AMORPHOUS ALPHA-OLEFIN POLYMERS, COMPOSITIONS CONTAINING THEM AND PROCESS FOR THE PREPARATION OF BRIDGED LIGAND | MONTELL TECHNOLOGY COMPANY BV (NL) | 2000-07-27 | — | — | WO | disclosed |
| EP-1017729-A2 | PROCESS FOR THE PREPARATION OF SUBSTANTIALLY AMORPHOUS ALPHA-OLEFIN POLYMERS, COMPOSITIONS CONTAINING THEM AND PROCESS FOR THE PREPARATION OF BRIDGED LIGAND | Montell Technology Company bv (NL) | 2000-07-12 | — | — | EP | disclosed |
| WO-2000001738-A2 | PROCESS FOR THE PREPARATION OF SUBSTANTIALLY AMORPHOUS ALPHA-OLEFIN POLYMERS, COMPOSITIONS CONTAINING THEM AND PROCESS FOR THE PREPARATION OF BRIDGED LIGAND | MONTELL TECHNOLOGY COMPANY BV (NL) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158356-A1 | Process for the preparation of substantially amorphous alpha-olefin polymers and compositions containing them and process for the preparation of bridged ligand | MACF1, SDC1, SDC2 | PTPN1 2634/4885CHRNA7 801/4885CDC25A 2223/4885 |
| US-20020169260-A1 | Process for the preparation of ligands for metallocene catalysts | SDC1, SDC2, SDC4 | PTPN1 2663/4885CHRNA7 1572/4885CDC25A 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.